Spectris AD by Cognito Therapeutics: status and timeline

Spectris AD

Slow cognitive decline in early Alzheimer's disease by stimulating gamma oscillations thought to enhance amyloid clearance and neural resilience.

PilotStage 3 of 5

HOPE pivotal trial fully enrolled with 670 patients; data expected 2027. FDA Breakthrough designation.

Updated 2 Jul 2025Checked 11 Oct0 updates this week

Milestones

Next · HOPE pivotal trial data read

HOPE pivotal trial enrollment complete2 Jul 2025Complete.
FDA Breakthrough Device designation2021Complete.
Series C funding $105MMar 2026Complete.
HOPE pivotal trial data readTarget Aug 2026Current milestone.
FDA approval applicationTarget Q4 2026Not yet reached.

Most important updates

Cognito Therapeutics completes enrollment in HOPE pivotal trial for Spectris AD with 670 Alzheimer's patients2 Jul 2025

Upcoming

2026FDA Breakthrough designation enables expedited review path (next)
Aug 2026HOPE pivotal trial data read
Q4 2026FDA approval application
2027HOPE trial top-line data release

Current obstacles

Translating animal findings to human brainGamma stimulation clears amyloid in mice; the human brain's complex cytoarchitecture and aged pathology may not respond the same way.
Patient adherence to daily treatmentChronic non-invasive treatments require daily discipline; older patients with cognitive decline may have adherence challenges.

Physics limits

Gamma frequency penetrationVisual flicker at 40 Hz is reliable only in superficial cortex; deeper brain regions may not receive sufficient stimulation intensity, limiting coverage.
Temporal window in Alzheimer'sBy the time Alzheimer's is diagnosed, substantial neurodegeneration has already occurred; intervention in mild cognitive impairment may work better but is harder to diagnose.

How it works

3 parts

Light and sound sync

Synchronized 40 Hz stimulation

The device emits flickering light and auditory clicks precisely locked at 40 Hz, driving neurons to oscillate at the gamma frequency.

Gamma resonance

Gamma oscillations enhance neural function

Animal studies show gamma oscillations increase microglia activation to clear amyloid and tau aggregates in Alzheimer's pathology.

Home use

Daily non-invasive wearable

Patients wear goggles that emit the light and use headphones for sound, making daily chronic treatment practical and safe in the home.

Spec sheet

Spec	Spectris AD
HOPE trial enrollment	670 patients^R (reported)
Stimulation frequency	40 Hz^R (reported)
Daily treatment time	1 hour^R (reported)

^R reported by the company

Papers & demos

1 item

2 Jul 2025demo
HOPE trial enrollment complete with 670 patients (opens medtechspectrum.com)Largest medical device trial exclusively focused on Alzheimer's patients; topline data expected mid-2026.

Update log

1 update

Wed 2 Jul 2025

Major: Cognito Therapeutics completes enrollment in HOPE pivotal trial for Spectris AD with 670 Alzheimer's patientsPressTest

About Cognito Therapeutics

The team behind Spectris AD

Cognito Therapeutics

Spectris AD, 40 Hz light-sound stimulation, Alzheimer's

Cognito Therapeutics develops non-invasive neuromodulation therapies using gammawave light and sound stimulation to slow Alzheimer's disease. The company's lead program, Spectris AD, is in pivotal trial with 670 patients enrolled.

Cognito's Spectris AD uses 40 Hz light and sound stimulation to target neurodegeneration in Alzheimer's disease.
The HOPE pivotal trial enrolled 670 patients to evaluate disease-modifying effects in early cognitive decline.
Series C funding of $105 million in March 2026 funds the pivotal trial and late-stage development.

cognitotx.com (opens cognitotx.com)Company profile →

Founded: 201610 yrs
Headquarters: United States
Status: Private
Valuation: $105Mdeal valueMar 2026
Raised: $105M1 round
Last round: Series C · $105MMar 2026
Works in: NeurotechNon-invasive
Coverage: 1 program · 2 updateslatest 5 Mar 2026checked 11 Oct
People: Christian Howell (opens cognitotx.com)CEOLi-Huei Tsai (opens cognitotx.com)Co-founderEd Boyden (opens cognitotx.com)Co-founder

Spec

Spectris AD

HOPE trial enrollment

670 patients^R (reported)

Stimulation frequency

40 Hz^R (reported)

Daily treatment time

1 hour^R (reported)